New drug duo aims to control colorectal cancer
NCT ID NCT06268015
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small pilot study is testing two immunotherapy drugs, botensilimab and balstilimab, in 16 people with advanced colorectal cancer that has not spread to the liver. Participants receive the drugs in 6-week cycles, and if the cancer progresses, standard chemotherapy is added. The goal is to see if the combination can shrink or stabilize tumors. This early research may help design larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Botensilimab and balstilimab (immunotherapy drugs)
What this could lead to
If this works, it could point toward a new treatment option for people with advanced colorectal cancer that has not spread to the liver.
What could go wrong
This is a very small, early-phase trial with only 16 participants. The results may not apply to everyone, and the drugs can cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University
Durham, North Carolina, 27710, United States